Taxus Cardium Pharmaceuticals Group Inc
Taxus Cardium Pharmaceuticals — Investor Presentation (September 2018)
24 slides from Taxus Cardium Pharmaceuticals's investor presentation, Sep 13, 2018
Slide 1: Angionetics: The Human Heart
IQ) angionetics THE HUMAN HEART
Slide 2: Leading the Revolution into New Frontiers of Cardiovascular Medicine
LEADING THE REVOLUTION INTO NEW FRONTIERS OF CARDIOVASCULAR MEDICINE
Slide 3: Slide 3
Slide 4: Slide 4
Slide 5: Coronary Artery Disease
CORONARY ARTERY DISEASE
Slide 6: Refractory Angina
REFRACTORY ANGINA
Slide 7: Listen
LISTEN
Slide 8: Measure
MEASURE
Slide 9: Angiogram
Angiogram
Slide 10: Genomics
Genomics DECODE
Slide 11: Slide 11
Slide 12: Slide 12
Slide 13: Gene Therapy
GENE THERAPY
Slide 14: Generx Product Candidate
NDC 1141-1111-11 Rx Onby GENERX” {alferminogene tadenavec) 6x10'vpi5 mL For intraceronary infusion ONY Single Use Vial PRODUCT CANDIDATE
Slide 15: Slide 15
Slide 16: Slide 16
Slide 17: Angiogenesis
ANGIOGENESIS
Slide 18: Finding New Ways to Heal
FINDING NEW WAYS TO HEAL
Slide 19: Perfusion: Medical Revascularization
Perfusion @ Reversible Perfusion Defect Before Treatment 4 Weeks Post- Generx Treatment 8 weeks Post- Generx Treatment MEDICAL REVASCULARIZATION
Slide 20: Revitalize
REVITALIZE
Slide 21: Slide 21
Slide 22: The Beauty of Biology
THE BEAUTY OF BIOLOGY ae THE POWER OF REGENERATIVE MEDICINE
Slide 23: AFFIRM Phase 3 Clinical Study
AFFIRM PHASE 3 CLINICAL STUDY Product Candidate 3 Generx (alferminogene tadenovec)
Slide 24: Product Candidate: Generx
Product Candidate - Generx (alferminogene tadenovec) Generx [AdSFGF-4] is a first in class, disease-modifying, single-dose, non-surgical, catheter-administered, angiogenic gene therapy that is designed to improve cardiac perfusion (blood flow) and to increase the supply of oxygenated blood in patien
Taxus Cardium Pharmaceuticals Group — Investor Presentation (September 2018) on 6ix